from haem and so increasing the load on the liver cell. This is rare as a single defect. In most instances, the haemolytic process is combined with a hypersensitivity reaction which decreases hepato-cellular function. Sulphonamides, for instance, can cause haemolysis but this is usually combined with a generalised hypersensitivity effect.
Interference with bilirubin uptake by the liver cell
Certain drugs interfere with the uptake of bilirubin into the liver cell and its transport to the microsomes for conjugation. Flavaspidic acid, the active principle of male fern, is a good example of this. This drug can be shown to constantly induce a mild unconjugated hyperbilirubinaemia. Very recently, Levi, Gatmaitan, and Arias (1968) have suggested that there are at least two carrier proteins, designated Y and Z, taking bilirubin through the liver cell. They believe that flavaspidic acid competes with the Z protein for the transport of unconjugated 75 DRUGS INTERFERING WITH BILIRUBIN
METABOLISM

Haemolytic reactions
Drugs may disturb bilirubin metabolism by haemolytic action, increasing bilirubin production Paper read at Southern England and South Wales Regional Meeting, London, July, 1969.
Serum binding ofbilirubin
Unconjugated bilirubin is transported to the liver in the plasma attached to albumin. Interference with this binding is particularly dangerous in the neonate (Fig. 1) . Organic anions such as salicylate or sulphonamides compete with the bilirubin for albumin and lead to its detachment, so causing kernicterus. An anomolous situation is therefore reported of kernicterus with lower than expected serum bilirubin levels. Infusions of albumin have been given therapeutically; these lower the cerebral but increase the serum bilirubin level (Diamond, 1966) .
The liver is the main organ involved with drug metabolism and it is, therefore, not surprising that it is often concerned with untoward reactions to drugs. The methods by which these arise are multiple, complex and often ill-understood. In general, three sets of circumstances must be considered (Sherlock, 1968) .
Firstly, there is the problem of specific interference with hepatic bilirubin metabolism at various points from the origin of the pigment from haem to its excretion into the bile. The resultant jaundice is fairly well understood. It is susceptible to animal experimentation and, during the last decade, research time has been lavished on it.
Secondly, the direct toxic effect of drugs on the !iver must be: considere~. This again.. can be studie~Sulphonamide 10 the expenmental animal, The third, 'hypersensi-® tivity' type affects only certain individuals in the Competes .. B+il.
human race. For this reason, basic research has not been possible in animals and the serious reactions AIb.
in man make volunteer and rechallenge studies unjustifiable.
Finally, the reaction to the drug may be modified by variation in the individual, whether because of age, disease or genetic make-up. This aspect will also be discussed. bilirubin and that this may be the mechanism of the jaundice following its administration. process is non-specific, the stimulating effect of the drug applying not only to itself but to all drugs handled by microsomal enzymes. Drugs in common use in any hospital, such as phenylbutazone or phenobarbitone, can induce hepatic microsomal enzymes even in those with liver disease. This illustrates some of the problems of drug testing, not only in patients with liver disease, but even in socalled 'normal' subjects. The status of the subject being tested in respect of induction of his hepatic enzymes is always uncertain. Apart from drug therapy, such factors as insecticides and other food additives are potent enzyme inducers.
TYPE OF REACTION IN LIVER CELL
Liver enlargement after drug therapy, observed without obvious light microscopical changes, is due to hypertrophy of the hepatocyte consequent upon enzyme induction (Barka and Popper, 1967 ). Electron-microscopy shows increase in smooth endoplasmic reticulum. This adaptive reaction to a drug is beneficial but may eventually become detrimental. Alone such hepatomegaly does not reflect an adverse reaction, but it is a signal for caution and for additional investigation for untoward effects of the drug.
UDP-glucuronyl transferase is a microsomal enzyme and is therefore inducible. This principle has been applied to the therapeutic reduction of unconjugated hyperbilirubinaemia. In infants with congenital non-haemolytic jaundice, reduction in the level of serum unconjugated bilirubin has followed the use of phenobarbital (Yaffe et al., 1966; Crigler and Gold, 1966) . This might be due to enzyme induction and phenobarbital has been given to mothers for the prevention of neonatal jaundice. Adult patients with deep unconjugated bilirubinaemia are unusual, but the jaundice can be treated by phenobarbital.
Interference with canalicular excretion
There have been many reports of jaundice in patients receiving various steroids including methyltestosterone, norethandrolone, norethisterone, norethynodrel and ethinyloestranol. The bilirubinaemia is conjugated so that it probably develops at a post microsomal level. It is associated with slight rises in serum alkaline phosphatase levels. Liver biopsy shows bile in liver cells, canaliculi and Kupffer cells. Electron microscopy shows abnormalities in the bile canaliculi once believed typical of drug jaundice but now thought to be non-specific and found in all forms of cholestasis. The jaundice is usually mild, the prognosis is excellent and chronic sequelae are unknown.
The mechanism of the cholestasis is uncertain. It seems to develop with orally administered, rather
Drugs disturbing bilirubin conjugation
Bilirubin is conjugated in the liver cell as a glucuronide, UDP-glucuronyl transferase being responsible. More than one enzyme may be concerned. These enzymes are located in the microsomes (smooth endoplasmic reticulum) of the liver cell. Unconjugated (lipid soluble) bilirubin is so converted into the water-soluble conjugated bilirubin glucuronide.
Two factors must be considered in discussing the effect of drugs on the conjugating process. The drug might inhibit the process or it could increase (induce) the enzyme and so facilitate conjugation.
Inhibition. The antibiotic novobiocin inhibits UDP-glucuronyl transferase and the resultant unconjugated hyperbilirubinaemia is particularly important in neonates. This may not be the only effect of the drug for in experimental animals it may also inhibit the excretion of conjugated bilirubin and therefore be acting at a post-microsomal level.
Stimulation. The problem of stimulation of drug metabolism by other drugs is an even more interesting one (so-called enzyme induction). The Genetics speCies\\ Type of Drug than parentally given drugs, suggesting that an alimentary portal of entry is important. The effect seems to be associated with certain configurations of steroid, namely C-17 alkyl substitutions in the testosterone molecule. DIRECT HEPATO-ToXICITY Certain substances produce a predictable liver injury when given to human subjects or to experimental animals (Sicot et al., 1969) . Other organs suffer in company with the liver and in most instances renal damage is more important than hepatic. Nausea, vomiting and diarrhoea reflect gastrointestinal injury and confusion and coma signify central nervous system involvement. These poisons, of which carbon tetrachloride is a good example, interfere particularly with protein synthesis by the cell. Tetracycline toxicity is interesting. When chlortetracycline and oxychlortetracycline were introduced into clinical medicine, they were already known to interfere with protein synthesis, and fatty change was noted in the liver. These observations were forgotten until 1963 when six women in the last trimester of pregnancy were given large doses (3.5-6.0 g/day, intravenously) of tetracycline for the treatment of pyelonephritis; death followed in hepato-renal failure. Autopsy showed a markedly fatty liver. Tetracycline toxicity was later associated with the grave condition of acute fatty liver of pregnancy. Although this can occur without tetracycline administration (Peters et al., 1967) on at least 20 occasions the drug has been associated with the fatty liver (Kunelis et al., 1965) . Toxicity is especially liable when protein synthesis is under stress or impaired as in pregnancy or malnutrition.
Other direct hepato-toxins include paracetamol, ferrous sulphate, methotrexate (Coe and Bull, 1968) , phosphorus and cytotoxic drugs.
Purine-analogues, such as 6-mercaptopurine, are known hepato-toxins and occasionally cause intrahepatic cholestasis and hepatic necrosis (Einhorn and Davidsohn, 1964) . These drugs may be particularly dangerous if the patient has underlying hepato-cellular disease, for instance, active chronic hepatitis. A rising serum bilirubin level may follow mercaptopurine therapy in this condition and this can even proceed to death in liver failure (Krawitt et al., 1967) .
Damage to vascular endothelium, causing an intra-hepatic Bud-Chiari syndrome, can follow direct radiation to the liver or the use of urethane (Reed and Cox, 1966) .
HEPATITIC-LIKE REACTION TO DRUGS
This is the most poorly understood reaction but perhaps the most important. It simulates acute virus hepatitis very closely. However, in limited studies, hepatitis associated (Australia) antigen has been absent from the serum (Fox et al., 1969) . It does not affect experimental animals. It carries a high mortality. Only a very small proportion of those taking the drug will have the reaction. There is no method of selecting who will be susceptible. The drugs most often associated with this hepatitis are the hydrazineamine oxidase inhibitors. Iproniazid was the first recorded cause and this was followed by phenelzine (Nardil) and many others. The complication is, however, by no means confined to this group. Earlier it has been related to cincophen. The uricosuric zoxozolamine has also been incriminated. It complicates treatment with some of the 'second line' antituberculous chemotherapeutic agents particularly ethionamide and cycloserine. The relationship to halothane anaesthesia will be discussed in more detail.
Halothane hepatitis. In 1963, fatal acute hepatic necrosis was first reported following surgical procedures under halothane anaesthesia and further cases followed. This led to a review by the National Research Council of the National Academy of Sciences in the United States (National Halothane Study, 1966) of clinical experience with the anaesthetic during the four-year period 1959-62. Deaths believed to be associated with massive hepatic necrosis and occurring within six weeks of operation were studied. This covered about 850,000 anaesthetics. In about 30 %of these, halothane was used. The overall mortality was 1.87 % for halothane and existing hepatic disease. Seven of the nine had received halothane; four of them more than once. In a survey of fulminant hepatitis cases, 36 of 150 had received halothane, 27 on more than one occasion and 32 died (Trey et al., 1968) . Recurrent attacks of hepatitis have even led to cirrhosis in an anaesthetist exposed to halothane (Klatskin and Kimberg,1969) .
Halothane hepatitis does seem to be a genuine entity. The hepatic injury usually follows multiple exposures so that patients having gynaecological orthopaedic or plastic surgical treatment, where multiple anaesthetics are necessary seem particularly at risk. On the average, fever occurs 6.5 days and jaundice after 10.4 days. Post-operative fever may be difficult to interpret for this affects 60 % of surgical patients whatever the anaesthetic used and in 98 % of these, it lasts three days. A leucocytosis and eosinophilia may be associated. The reaction does not appear to be dose-dependent and the initial exposure is often minor. There does not seem to be an increased incidence in patients with underlying hepatic or biliary disease. Halothane is, in fact, a very satisfactory anaesthetic for performing such operations as portacaval anastomoses in cirrhotic patients. Histologically, the hepatic lesion appears to be indistinguishable from that of viral hepatitis.
It can be concluded that halothane, because of its non-explosive nature, ease of administration, infrequency of serious side effects, and overall lower mortality rate, is deservedly the most widely used inhalational anaesthetic. In some cases, however, its administration has been followed by serious liver damage, especially in patients subjected to repeated exposures. The use of halothane should be avoided if a previous exposure has been followed by otherwise unexplained fever whether or not accompanied by jaundice.
CHOLESTATIC SENSITIVITY REACTIONS
This type is particularly associated with drugs of the phenothiazine group, of which chlorpromazine is a good example. The reaction is unrelated to dose; it can occur after only one 20 mg tablet. In 80--90 % of cases, the onset is in the first four weeks and in about a half it is between the first and third week of treatment. The incidence is low probably affecting less than 0.5 % of those receiving the drug.
There are associated phenomena of a generalised hypersensitivity reaction. Administration of the drug may cause an antigen-antibody reaction on the surface of the cells to which the antibody is fixed, thereby producing injury within a specific organ, in this case, the liver.
The reaction is usually a mild one lasting only a few days. If a history of taking the drug is not obtained, a mistaken diagnosis of surgical jaundice may be made and the patient subjected to unnecessary laparotomy. Occasionally the cholestasis is very prolonged, lasting many months and primary biliary cirrhosis may be simulated. The onset, however, is always more acute, hepatic histology can usually be distinguished and the mitochondrial immunofluorescent test, so often positive in primary biliary cirrhosis (Walker et al., 1965) is almost invariably negative.
'MIXED' HYPERSENSITIVITY REACTIONS
A number of other drugs cause jaundice of mixed hepato-cellular and cholestatic types. The condition is therefore of intermediate severity between the hepatic ('Iproniazid') and the cholestatic ('Chlorpromazine') types. The associated hypersensitivity phenomena are marked and include fever, rashes and blood and tissue eosinophilia and often other blood dyscrasias, They are more frequent with multiple exposures. They usually appear within four weeks of the patient starting the drug. The reaction to para-amino salicylate is fairly typical of the group. The sulphonamides have also been reported to cause a hepato-toxicity of this type on 107 occasions. Erythromycin estolate rarely causes the reaction, the estolate is at fault, and not the macrolide antibiotic itself.
INDIVIDUAL VARIATION
The chance of an individual reacting adversely to a drug cannot usually be predicted. In the case of the liver, specific interference of a drug with serum bilirubin metabolism can be anticipated. The reaction to direct hepato-toxins can also largely be foretold on a dose basis. The more serious hypersensitivity reactions, however, appear with no warning and with no known method of prediction.
Certain individual factors affecting the response of the liver to a drug will now be considered.
Age
The neonate is particularly susceptible to drugs which interfere with bilirubin metabolism. Firstly the hepatic conjugating mechanism is slow to develop and is deficient especially in the premature infant. Secondly, the effects of an unconjugated hyperbilirubinaemia are much more serious than in the adult for bilirubin encephalopathy (or kernicterus) may be a consequence.
Drugs, such as the sulphonamides which interfere with the binding of bilirubin to serum albumin, must be avoided. In any case, serum albumin levels tend to be low in the neonate. Infusions of albumin have been given to jaundiced neonates to increase the binding of the serum for bilirubin and so minimise its passage through the blood-brain barrier (Diamond and Schmid, 1966) .
Drugs such as novobiocin which inhibit the conjugating enzyme, will exacerbate neonatal jaundice and should not be given.
Nutrition
The elderly or undernourished patient with decreased or stressed protein synthesis reacts poorly to hepato-toxins which depress protein synthesis further. This also applies to the pregnant woman whose synthetic powers may already be stretched to capacity.
Underlying disease
If hepatic detoxication is reduced a drug, even if given in normal doses, may be hazardous. This may be illustrated by a patient with severe migraine who was taking large doses of ergot when she developed severe acute virus hepatitis (Whelton et al., 1968) . The ergot was continued but was not detoxicated by the damaged liver, so that severe gangrene of all the extremities developed and she ultimately died.
Renal disease, for instance pyelonephritis, is probably important in potentiating the hepatotoxicity of tetracycline.
Previous drug therapy
This has already been discussed under enzyme induction. The importance of noting all drugs being taken by an individual who becomes jaundiced must be stressed.
Oral contraceptives
These provide examples of individual variation in response to a drug. Most, but not all, oral contraceptive drugs contain an oestrogen and a progestin, either or both of which is a C-17 substituted testosterone derivative. They therefore may have potentially cholestatic properties (Ockner and Davidson, 1967) . The rarity of cases of jaundice among the many millions of women taking the pill has various possible explanations. In part it is due to the very small doses of cholestatic drug consumed. In part, it is related to the underlying susceptibility, possibly genetic, of the women being treated. It is interesting that the only large series of patients reported with 79 jaundice complicating oral contraceptive therapy, have come from Scandinavia and Chile. It is from these countries that the largest series of patients with cholestatic jaundice of the last trimester of pregnancy has been described. Moreover, about half the patients who react to the pill have suffered from this condition. This suggests that the sufferers have an undue sensitivity both to some steroid contained in the pill and to one produced during pregnancy. One such patient developed the same cholestatic symptoms as she had experienced in eight pregnancies when challenged with ethanyl oestradiol, a synthetic C-17 alkyl substituted steroid (Somayaji et 01., 1968) . Oral contraceptives of this type should not be given to patients who have experienced jaundice or itching in the last trimester of pregnancy. Patients with underlying liver disease may also react abnormally (Mulligan and Sherlock, 1968) .
SUMMARY
Untoward hepatic reactions to drugs are classified according to the possible mechanism. Interference with bilirubin metabolism, direct hepatotoxicity, hepatic and cholestatic hypersensitivity reactions are recognised. The role of hepatic enzyme induction in drug metabolism and in therapy is discussed.
Individual variation in the hepatic reactions to a drug are illustrated by the neonate, the pregnant, the state of hepato-cellular function and by the response to some oral contraceptives.
